Premium
Vitamin D has no impact on outcomes after HSCT in children—A retrospective study
Author(s) -
Bajwa Rajinder P. S.,
Taylor Kimberly,
Hoyt Amanda,
Kamboj Manmohan K.,
Stanek Joseph,
Mahadeo Kris M.,
Alsaedi Hawazen,
AbdelAzim Hisham,
O’Kane Sara,
Martin Paul L.,
Stafford Lauren A.,
Dvorak Christopher C.
Publication year - 2021
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.14008
Subject(s) - medicine , vitamin d and neurology , retrospective cohort study , malignancy , hematologic malignancy , prospective cohort study , vitamin d deficiency , hematopoietic stem cell transplantation , vitamin , pediatrics , transplantation
Abstract Vitamin D not only plays an important role in bone metabolism but is also involved in multiple immune‐mediated processes in the body which may be adversely affected in those with low levels. Most pediatric studies evaluating the association of vitamin D in patients undergoing allogeneic HSCT are single‐center studies. We present the results of retrospective study at 5 centers across the United States in pediatric patients undergoing allogeneic HSCT. (VDD) and (VDI) were defined by vitamin D levels of <20 ng/ml and 21–30 ng/ml, respectively. The mean vitamin D levels pre‐HSCT, day +30, and +100 were suggestive of VDI, but normalized thereafter. We compared the transplant characteristics and outcomes in 233 patients with VDD and VDI and those with normal levels and found no statistical difference in neutrophil or platelet engraftment, infections (viral, bacterial, or fungal) post‐HSCT, length of hospital stay during HSCT, graft failure, acute or chronic GvHD, survival at day +100 and 1 year, or relapse of primary malignancy. We conclude that VDI or deficiency does not affect any of the common transplant variables after allogeneic HSCT in children. There is a need of a large multicenter prospective study to evaluate its role further.